Patient, disease, and transplant-related characteristics
| Characteristic . | CNI based N = 270 . | PTCy N = 176 . | P value . |
|---|---|---|---|
| Median age (range), y | 34 (18-66) | 33 (19-69) | .19 |
| Sex, n (%) | .8 | ||
| Female | 110 (41) | 73 (41) | |
| Male | 160 (59) | 103 (59) | |
| Karnofsky performance status, n (%) | .06 | ||
| ≥90 | 209 (80) | 148 (87) | |
| <90 | 53 (20) | 22 (13) | |
| Missing | 8 | 6 | |
| Hematopoietic cell transplantation-comorbidity index, n (%) | .23 | ||
| Low | 148 (66) | 93 (58) | |
| Intermediate | 39 (17) | 33 (20) | |
| High | 37 (17) | 35 (22) | |
| Missing | 46 | 15 | |
| HL status | .32 | ||
| Chemosensitive | 229 (85) | 146 (83) | |
| Refractory | 41 (15) | 30 (17) | |
| Number of prior lines, n (%) | .29 | ||
| 1 | 61 (25) | 33 (20) | |
| 2 | 33 (14) | 19 (12) | |
| 3 | 145 (61) | 112 (68) | |
| Missing | 31 | 12 | |
| Prior autologous stem cell transplantation | 207 (77) | 117 (67) | .01 |
| Median time from diagnosis to HSCT, mo (range) | 35 (4-278) | 40 (5-368) | .08 |
| Type of donor, n (%) | <.001 | ||
| MSD | 200 (74) | 88 (50) | |
| MUD | 70 (26) | 88 (50) | |
| Stem cell source, n (%) | .14 | ||
| Bone marrow | 25 (9) | 24 (14) | |
| Peripheral blood | 245 (91) | 152 (86) | |
| Female donor to male recipient, n (%) | 60 (22) | 32 (19) | .33 |
| RIC regimen, n (%) | 180 (69) | 132 (75) | .1 |
| Conditioning regimen, n (%) | NA | ||
| Flu + Bu | 69 (26) | 60 (34) | |
| Flu + Mel | 75 (28) | 17 (10) | |
| Flu + Cy | 38 (14) | 12 (7) | |
| TBI-based | 48 (18) | 41 (23) | |
| Other | 40 (14) | 46 (26) | |
| GVHD prophylaxis, n (%) | NA | ||
| PTCy + 2 drugs | - | 126 (72) | |
| PTCy + 1 drug | - | 41 (23) | |
| PTCy alone | - | 9 (5) | |
| CsA | 21 (8) | - | |
| CsA + MMF | 74 (27) | - | |
| CsA + MTX | 137 (51) | - | |
| Other | 38 (14) | - |
| Characteristic . | CNI based N = 270 . | PTCy N = 176 . | P value . |
|---|---|---|---|
| Median age (range), y | 34 (18-66) | 33 (19-69) | .19 |
| Sex, n (%) | .8 | ||
| Female | 110 (41) | 73 (41) | |
| Male | 160 (59) | 103 (59) | |
| Karnofsky performance status, n (%) | .06 | ||
| ≥90 | 209 (80) | 148 (87) | |
| <90 | 53 (20) | 22 (13) | |
| Missing | 8 | 6 | |
| Hematopoietic cell transplantation-comorbidity index, n (%) | .23 | ||
| Low | 148 (66) | 93 (58) | |
| Intermediate | 39 (17) | 33 (20) | |
| High | 37 (17) | 35 (22) | |
| Missing | 46 | 15 | |
| HL status | .32 | ||
| Chemosensitive | 229 (85) | 146 (83) | |
| Refractory | 41 (15) | 30 (17) | |
| Number of prior lines, n (%) | .29 | ||
| 1 | 61 (25) | 33 (20) | |
| 2 | 33 (14) | 19 (12) | |
| 3 | 145 (61) | 112 (68) | |
| Missing | 31 | 12 | |
| Prior autologous stem cell transplantation | 207 (77) | 117 (67) | .01 |
| Median time from diagnosis to HSCT, mo (range) | 35 (4-278) | 40 (5-368) | .08 |
| Type of donor, n (%) | <.001 | ||
| MSD | 200 (74) | 88 (50) | |
| MUD | 70 (26) | 88 (50) | |
| Stem cell source, n (%) | .14 | ||
| Bone marrow | 25 (9) | 24 (14) | |
| Peripheral blood | 245 (91) | 152 (86) | |
| Female donor to male recipient, n (%) | 60 (22) | 32 (19) | .33 |
| RIC regimen, n (%) | 180 (69) | 132 (75) | .1 |
| Conditioning regimen, n (%) | NA | ||
| Flu + Bu | 69 (26) | 60 (34) | |
| Flu + Mel | 75 (28) | 17 (10) | |
| Flu + Cy | 38 (14) | 12 (7) | |
| TBI-based | 48 (18) | 41 (23) | |
| Other | 40 (14) | 46 (26) | |
| GVHD prophylaxis, n (%) | NA | ||
| PTCy + 2 drugs | - | 126 (72) | |
| PTCy + 1 drug | - | 41 (23) | |
| PTCy alone | - | 9 (5) | |
| CsA | 21 (8) | - | |
| CsA + MMF | 74 (27) | - | |
| CsA + MTX | 137 (51) | - | |
| Other | 38 (14) | - |
Bu, Busulfan; Flu, Fludarabine; Mel, Melphalan; MTX, Methotrexate; NA, not applicable; TBI, total body irradiation.